Evidence map›Paper›PMID 42361800›Full record

ArticleCell reports. Medicine2026

Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4

Alexander K Tsai, John R Lozada, Philippa R Kennedy, David Moline, Rachana Pandey, Riley C Lyons, Christine Luo, Rulin Wang, Ali T Arafa, Elise L Femino and 17 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Alexander K TsaiDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA.
John R LozadaDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Philippa R KennedyDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
David MolineDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Rachana PandeyInstitute for Health Informatics, University of Minnesota, Minneapolis, MN 55455, USA; Clinical Translational Science Institute, University of Minnesota, Minneapolis, MN 55415, USA.
Riley C LyonsDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Christine LuoDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Rulin WangSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Ali T ArafaDepartment of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Elise L FeminoDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Sarah ZipkowitzSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Alexis FigueroaDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Patrick J McCannGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Matthew C DallosGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Andrew ElliottCaris Life Sciences, Phoenix, AZ 85040, USA.
Paari MuruganDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.
Martin FelicesDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Nicholas A ZorkoDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Badrinath R KonetyAllina Health Cancer Institute, Minneapolis, MN 55407, USA.
Scott M DehmMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.
Jeffrey S MillerDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Steven S ShenInstitute for Health Informatics, University of Minnesota, Minneapolis, MN 55455, USA; Clinical Translational Science Institute, University of Minnesota, Minneapolis, MN 55415, USA.
Elizabeth A ThompsonDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Laura A SenaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Srinivasan YegnasubramanianSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Justin HwangDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Emmanuel S AntonarakisDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: anton401@umn.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI HEATHER Hammond NELSON · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI GELLER, MELISSA ANN · 2005 to 2025
$38.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Translational imaging biomarkers of the tumor microenvironment in early prostate cancerU54CA274370 · NCI · JOHNS HOPKINS UNIVERSITY · PI Srinivasan Yegnasubramanian · 2022 to 2026
$9.1M
SPORE in Prostate CancerP50CA272391 · NCI · JOHNS HOPKINS UNIVERSITY · PI Srinivasan Yegnasubramanian · 2024 to 2026
$9.0M
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumorsR35CA283892 · NCI · UNIVERSITY OF MINNESOTA · PI Jeffrey S. Miller · 2023 to 2026
$3.7M
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)R37CA288972 · NCI · UNIVERSITY OF MINNESOTA · PI Justin H. Hwang · 2024 to 2026
$1.1M
Tissue-Resident Adaptive CD56bright NK Cell Responses in CancerF30CA294723 · NCI · UNIVERSITY OF MINNESOTA · PI John Roy Lozada · 2024 to 2026
$142k
NCI NIH HHS F30 CA294723NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA077598NCI NIH HHS P50 CA272391NCI NIH HHS R35 CA283892NCI NIH HHS R37 CA288972NCI NIH HHS U54 CA274370NIGMS NIH HHS T32 GM008244
6 · The paper itself

Abstract

Mismatch repair deficiency (dMMR) and microsatellite instability (MSI-H) are rare in prostate cancer, occurring in 2%-4% of cases. These defects result in increased genomic instability and elevated tumor mutational burden (TMB), which can support responses to immune checkpoint inhibitors (ICIs). Here, we report a patient with locally advanced Gleason 5 + 5 = 10 prostatic adenocarcinoma harboring MSH2 and MSH6 genomic deletions with ultrahigh TMB (>250 mutations/megabase) in whom pembrolizumab resulted in a striking complete radiographic, pathologic, and molecular response. Using digital-spatial microscopy, single-cell RNA/T cell receptor (TCR) sequencing, and multiplex cytometry, we identify atypical tumor-infiltrating T cells with natural killer-like phenotypes and CD4

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDNA Mismatch RepairImmunotherapyKiller Cells, NaturalProstatic NeoplasmsAdenocarcinomaAntibodies, Monoclonal, HumanizedHumansImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMaleMicrosatellite InstabilityMutS Homolog 2 ProteinAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsMutS Homolog 2 Proteinpembrolizumabcomplete pathologic responsecytotoxic T lymphocytedMMRimmune checkpoint inhibitorimmunotherapyMSI-highpembrolizumabprostate cancerT cellTMB

Identifiers

PMID42361800
PMCPMC13400160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.